Thymosin Alpha-1 + LL-37 Blend

Last updated: October 17, 2026No human trials on this combination

Ask about Thymosin Alpha-1 + LL-37 Blend in chat →

How this combination works

The community rationale for pairing Thymosin Alpha-1 (Ta1) and LL-37 rests on the hypothesis that they represent complementary arms of immune defense: Ta1 amplifying adaptive T-cell-mediated immunity and LL-37 providing broad-spectrum innate antimicrobial coverage. Ta1 enhances T-cell differentiation and thymic output, activates plasmacytoid and myeloid dendritic cells through TLR7/MyD88 signaling, suppresses MDSCs via VEGF/HIF-1alpha downregulation, and upregulates CD40/CD40-L while downregulating PDL-1/PD-1 in DC-T cell immune synapses. LL-37 directly disrupts microbial membranes and inhibits biofilm formation across bacteria, fungi, and viruses, promotes neutrophil extracellular trap formation, and modulates NF-kB, MAPK/ERK, and NLRP3 innate signaling. The theoretical appeal is that LL-37's innate antimicrobial barrier and Ta1's adaptive T-cell amplification act on distinct immune compartments and are thus mechanistically complementary. This rationale is entirely mechanistic inference. No study in either component file tests these two compounds together. Both agents carry documented counterpoints: LL-37 has pro- and anti-inflammatory activity that is highly context-dependent and concentration-dependent, and is cytotoxic to multiple human cell types at 1-10 uM concentrations in vitro. Ta1 showed a potential harm signal in COVID-19 patients under 60 years (HR 1.67 for 28-day mortality) in the TESTS phase 3 RCT and was associated with higher non-recovery rates in certain COVID-19 patient subgroups in a large multicenter Chinese cohort. The community rationale for stacking these agents is therefore labelled: mechanistic inference only, with no combination evidence and documented context-dependent risks for each component.

Combined mechanism

Thymosin Alpha-1 (Ta1) is a 28-amino-acid endogenous peptide processed in vivo from prothymosin alpha by lysosomal asparaginyl endopeptidase (legumain). It acts through Toll-like receptors, particularly TLR7, in both myeloid and plasmacytoid dendritic cells, activating downstream signaling pathways and immune-related cytokine production. In the tumor microenvironment, Ta1 binds phosphatidylserine on apoptotic cells, is internalized by macrophages, and activates SHIP1 via TLR7/MyD88, reversing M2 polarization of tumor-associated macrophages and enhancing CD4+ and CD8+ T cell responses. Ta1 also acts as a microRNA chaperone, binding miR-146a-5p and protecting it from lysosomal RNase A degradation to enable TLR7 activation in dendritic cells, licensing DC maturation, migration, and tumor antigen presentation. Ta1 stimulates T-cell differentiation and proliferation and restores exhausted T cells, suppresses MDSCs via VEGF/HIF-1alpha downregulation, and upregulates CD40/CD40-L while downregulating PDL-1/PD-1 in DC-T cell synapses. It exhibits anti-inflammatory and antioxidant properties. LL-37 is the sole human cathelicidin, encoded by the CAMP gene as precursor hCAP18 and proteolytically cleaved extracellularly to its active form. It exerts broad-spectrum antimicrobial activity against bacteria, fungi, viruses, and parasites through membrane disruption, pore formation, biofilm matrix degradation, and interference with viral entry and replication. Against SARS-CoV-2, LL-37 binds the Spike protein S2 subunit and accessory proteins ORF7a and ORF8, inhibiting TMPRSS2-mediated priming and membrane fusion. LL-37 promotes neutrophil extracellular trap formation in a dose-dependent manner and modulates signaling via NF-kB, Akt, MAPK/ERK, Wnt/beta-catenin, and NLRP3 inflammasome pathways. It is cytotoxic to multiple human cell types at 1-10 uM concentrations in vitro, is highly susceptible to proteolytic degradation in vivo with rapid hepatic clearance after intravenous administration in mice, and elevated LL-37 levels have been associated with promoting thrombosis in animal models. LL-37 has both pro- and anti-inflammatory roles depending on peptide concentration, receptor binding, disease stage, and tissue microenvironment. The two compounds act on different receptor systems and immune compartments: Ta1 primarily through TLR7 and adaptive T-cell circuits; LL-37 primarily through direct membrane action and innate signaling via TLR4, NF-kB, MrgX2, FPR2, and NLRP3 in multiple innate immune cell types. No human pharmacokinetic or pharmacodynamic interaction data exist for the combination. No study in either component file tests these two compounds together.

What each component does

Thymosin Alpha-1View full peptide page →LL-37View full peptide page →

Evidence base for this combination

No combo-specific RCTNo study — in vitro, animal, or human — testing Thymosin Alpha-1 and LL-37 in combination is cited in either compound's approved file (reviewed 2026-10-17). Any rationale for pairing them is mechanistic inference from each compound studied independently, not evidence that the combination is effective or safe.

Safety considerations for this combination

No combination-specific safety data exist for Thymosin Alpha-1 + LL-37. No study testing the two compounds together has been identified in either component's approved file. All safety signals below derive from each compound studied independently. Both approved component files (reviewed 2026-10-17)
In the TESTS phase 3 RCT (n=1089, China), Ta1 showed no statistically significant reduction in 28-day all-cause mortality in sepsis overall (HR 0.99; 95% CI 0.77-1.27; P=0.93) and a potential harm signal in patients under 60 years (HR 1.67). A large multicenter Chinese cohort (n=2282) found Ta1 associated with higher non-recovery rate in COVID-19 (OR 1.5, 95% CI 1.1-2.1), particularly in patients with SOFA >=2, ICU admission, and lower PaO2/FiO2. A separate retrospective study (n=275) found no significant benefit on T-cell restoration or viral clearance. Ta1: PMID 39814420, 34408744, 34149679
LL-37 is cytotoxic to multiple human cell types — including osteoblasts, vascular smooth muscle cells, periodontal ligament cells, neutrophils, airway epithelial cells, and T cells — at 1-10 uM concentrations in vitro. Very high concentrations (~300 uM) are detected in psoriatic lesions, implying potential host cell toxicity at sites of high endogenous expression or exogenous administration. LL-37: PMID 40063262
Elevated LL-37 was associated with hypercoagulation in COVID-19 patients (negatively correlated with thrombin time, positively with fibrinogen); cathelicidin injection promoted thrombosis in vivo in animal models and cathelicidin deletion inhibited thrombosis. LL-37: PMID 35596804
LL-37 promotes cancer cell migration and invasiveness in most studied epithelial tumors including breast, hepatocellular, and squamous cell carcinomas. In hepatocellular carcinoma, LL-37 enhanced EMT, migration, and invasion via HER2/EGFR-MAPK/ERK signaling and was associated with more frequent lung metastases in a hematogenous metastasis mouse model. LL-37: PMID 41916132, 36656313
LL-37 promotes neutrophil extracellular trap (NET) formation in a dose-dependent manner; NETs are implicated in immunothrombosis and chronic inflammatory pathologies including chronic rhinosinusitis. LL-37: PMID 31046155
LL-37 is highly susceptible to proteolytic degradation in vivo, with rapid hepatic clearance observed after intravenous administration in mice. This limits systemic bioavailability and makes community dosing protocols — which are not based on human pharmacokinetic data — difficult to evaluate for actual systemic exposure. LL-37: PMID 38972467, 41270816
LL-37 induced apoptosis in coronary artery endothelial cells and activated TLR4-NF-kB-NLRP3 pro-inflammatory signaling in a Kawasaki disease model. LL-37 also induced endothelial-to-mesenchymal transition in human umbilical vein endothelial cells via Akt and NF-kB activation, suggesting potential for atherosclerotic pathogenesis. LL-37: PMID 37773705, 40690262
LL-37 has a dual and context-dependent role in inflammatory bowel disease — protective in some contexts but pathogenic in others depending on peptide concentration, receptor binding, disease stage, and tissue microenvironment. Analogous context-dependence is relevant to any systemic administration. LL-37: PMID 42095322

Contraindications

Thymosin Alpha-1 is restricted by the FDA from compounding under 503A pharmacy regulations as of 2023. LL-37 has no FDA-approved therapeutic indication. Neither compound is approved for human use in the United States. The combination has not been evaluated in any human clinical trial. The absence of documented combination-specific contraindications reflects a lack of clinical evaluation, not established safety. Ta1 regulatory restriction: PMID 38308608; LL-37 regulatory status per its approved file (not stated in reviewed literature — requires manual verification)
Both Thymosin Alpha-1 and LL-37 are immunostimulatory agents acting on overlapping innate immune signaling nodes (TLRs, NF-kB). Concurrent administration of two immunostimulatory peptides carries theoretical risk of additive or synergistic immune activation. Use in individuals with autoimmune disease, systemic inflammatory conditions, or active cytokine-driven illness has not been studied for either compound in combination and is a recognized concern given each compound's broad immunomodulatory activity. Mechanistic inference from Ta1 (PMID: 27450734, 35364609) and LL-37 (PMID: 41270816, 42095322); no combination study available
Individuals on immunosuppressive therapy — including organ transplant recipients and patients receiving corticosteroids or biologic agents — should not use either compound without medical supervision. Immunostimulation may counteract therapeutic immunosuppression; the magnitude of this risk in the combination setting is not quantifiable from available data. Mechanistic inference from both compound files; no combination study
LL-37 promotes cancer cell migration and invasiveness in most studied epithelial tumors including breast, hepatocellular, and squamous cell carcinomas, and activates oncogenic Wnt/beta-catenin and MAPK/ERK signaling in lung tumor cells. Its oncological role is context-dependent and cancer-type-specific: anti-cancer in colon and gastric cancer and some hematologic malignancies, but tumor-promoting in multiple others. Co-administration with Ta1 does not neutralize the cancer-promoting risk of LL-37 in susceptible tumor types. LL-37: PMID 41916132, 31149039, 29843147
Elevated LL-37 levels have been associated with hypercoagulation in COVID-19 patients, and cathelicidin injection promoted thrombosis in animal models while cathelicidin deletion inhibited it. Individuals with pre-existing hypercoagulable states, cardiovascular disease, or a history of thrombotic events should exercise particular caution. LL-37: PMID 35596804
The WADA prohibited status of Thymosin Alpha-1 and LL-37 is not stated in the reviewed literature for either compound and requires manual verification before use by competitive athletes. Until confirmed, athletes subject to anti-doping rules should treat both compounds as requiring individual sport-federation review. Regulatory status sections of both approved component files (both listed as 'not stated in reviewed literature — requires manual verification')